Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End Stage Renal Disease on Hemodialysis (Diagnosis) Clear all
Not yet recruiting Phase 1Phase 2 Interventional

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

NCT06609343
View directory record Official record
Conditions
End Stage Renal Disease, Fatigue
Interventions
Bupropion Hydrochloride 150 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

NCT03873038
View directory record Official record
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 4 Interventional

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

NCT00294866
View directory record Official record
Conditions
Kidney Failure
Interventions
Paricalcitol
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Evergreen Park, Illinois • Kalamazoo, Michigan • West Orange, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2010 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 23, 2026, 8:41 PM EDT
Completed No phase listed Observational

Blood Volume Analysis and Renal Outcomes in Hemodialysis

NCT02717533
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Actual Impaired Fluid Volume, Kidney Failure
Interventions
dry weight adjustment
Other
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 23, 2026, 8:41 PM EDT
Active, not recruiting Not applicable Interventional

Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans

NCT04064086
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Hemodialysis, Peritoneal Dialysis
Interventions
Comprehensive Pre-ESRD Patient Education (CPE), Provision of the freely available resources for Kidney Disease Education
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis

NCT04985383
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
AKST1210 S-15 at 250 mL/min, AKST1210 S-15 at 450 mL/min, AKST1210 S-25 at 250 mL/min, AKST1210 S-25 at 450 mL/min, AKST1210 S-35 at 250 mL/min, AKST1210 S-35 at 450 mL/min
Device
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Gallup, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

The EvAluation of TaBlo In-CLinic and In-HOme

NCT02460263
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

NCT00742716
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

NCT00316472
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Niacinamide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2009 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

NCT00268957
View directory record Official record
Conditions
Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
Interventions
Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 23, 2026, 8:41 PM EDT
Terminated Phase 4 Interventional Results available

Bupropion for Depression in ESRD Patients on Hemodialysis

NCT02238977
View directory record Official record
Conditions
Major Depression, End Stage Renal Disease
Interventions
Fluoxetine, Bupropion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis

NCT00004429
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
growth hormone
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Early Phase 1 Interventional

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

NCT05705414
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 8:41 PM EDT
Withdrawn Phase 4 Interventional

Spironolactone Safety in Dialysis Patients

NCT00328809
View directory record Official record
Conditions
End Stage Renal Disease, Congestive Heart Failure
Interventions
spironolactone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

NCT00943995
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Dialysis
Interventions
somatropin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

NCT02289703
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Rivaroxaban 15 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Not applicable Interventional

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

NCT06581393
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
Interventions
Moda-flx Hemodialysis System
Device
Lead sponsor
Diality Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ontario, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Not applicable Interventional

The Effect of Intradialytic Exercise on the Physical Function of People Undergoing Hemodialysis

NCT03944824
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Frail Elderly Syndrome
Interventions
Exercise Plan using resistance bands, Modified Fried Frailty Scale
Other · Diagnostic Test
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milpitas, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Helping Olfaction and Nutrition On Renal Replacement

NCT02479451
View directory record Official record
Conditions
End Stage Renal Disease, Olfactory Disorders
Interventions
Theophylline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 23, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 8:41 PM EDT